MUTTA

What this means for you

Not registered yet, but its 31 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

97435951

Mark type

Stylized text

Filed

31 May 2022

Published for opposition

18 Jul 2023

Attorney of record

Christopher D. Olszyk, Jr.

Goods and services

• Class 001 — Chemicals: Multitarget, multiepitope, multivalent centralized antibody molecule structure used to incorporate multiple target antigen binders into a single antibody, namely, multi-specific therapeutic antibodies for scientific and medical research
• Class 005 — Pharmaceuticals: Multitarget, multiepitope, multivalent centralized antibody molecule structure used to incorporate multiple target antigen binders into a single antibody, namely, multi-specific reagent antibodies for medical diagnosis purposes
• Class 042 — Scientific and technological services: Providing prescription drug research information relating to cancer drugs
• Class 044 — Medical, beauty and agricultural services: Providing healthcare information regarding cancer drugs and cancer treatment

Owner

• Aarvik Therapeutics, Inc., Hayward, CA, US
• Aarvik Therapeutics, Inc., Hayward, CA, US

Prosecution history

• 10 Sept 2026 — STATEMENT OF USE PROCESSING COMPLETE
• 08 Sept 2026 — USE AMENDMENT FILED
• 08 Sept 2026 — TEAS STATEMENT OF USE RECEIVED
• 17 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 17 Jul 2026 — SOU EXTENSION 5 GRANTED
• 05 Mar 2026 — SOU EXTENSION 5 FILED
• 16 Jul 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
• 05 Mar 2026 — SOU TEAS EXTENSION RECEIVED
• 12 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 11 Sept 2025 — SOU EXTENSION 4 GRANTED
• 11 Sept 2025 — SOU EXTENSION 4 FILED
• 11 Sept 2025 — SOU TEAS EXTENSION RECEIVED
• 27 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 27 Feb 2025 — SOU EXTENSION 3 GRANTED
• 27 Feb 2025 — SOU EXTENSION 3 FILED